KYNMOBI Market Size, Forecast, and Market Insight - 2032
상품코드:1462263
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
킨모비 설하 필름에는 비에르고린 도파민 작용제인 아포모르핀 염산염이 함유되어 있습니다. 아포모르핀 염산염은 상온에서 물과 알코올에 잘 녹는 흰색에서 반짝이는 회백색 결정 또는 백색 분말입니다. KYNMOBI는 현재 유럽에서 임상 개발 중입니다.
KYNMOBI를 처음 복용하기 3일 전부터 트리메토벤즈아미드와 같은 구토방지제를 함께 복용하는 것이 권장되며, KYNMOBI의 용량 범위는 1회 10-30mg이며, 필요에 따라 설하로 투여하며, KYNMOBI는 최소 2시간 간격으로 투여해야 합니다.
KYNMOBI는 비엘고린형 도파민 작용제이며, in vitro에서 도파민 D4 수용체에 높은 친화력을 나타내며, 도파민 D2, D3, D5 및 아드레날린성 a1D, a2B, a2C 수용체에는 중간 정도의 친화력을 나타냅니다.
앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 회사는 병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, KYNMOBI의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 파킨슨병에 대한 다른 신흥 제품들이 KYNMOBI와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 파킨슨병 치료제 KYNMOBI 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 서론
제2장 파킨슨병에서의 KYNMOBI 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
규제 마일스톤
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신흥 치료법)
제5장 KYNMOBI 시장 평가
파킨슨병용 KYNMOBI 시장 전망
주요 7개국 분석
주요 7개국의 파킨슨병 치료제 KYNMOBI 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH
영문 목차
영문목차
"KYNMOBI Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about KYNMOBI for Parkinson's disease in the seven major markets. A detailed picture of the KYNMOBI for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the KYNMOBI for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KYNMOBI market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary:
KYNMOBI sublingual film contains apomorphine hydrochloride, a nonergoline dopamine agonist. Apomorphine hydrochloride is white to glistening grayish crystals or white powder sparingly soluble in water and alcohol at ambient temperature. KYNMOBI is currently in clinical development in Europe.
Dosage and administration
For sublingual administration only
A healthcare provider should supervise dose initiation
Treatment with a concomitant antiemetic, e.g., trimethobenzamide, is recommended, beginning 3 days before an initial dose of KYNMOBI
The dose range for KYNMOBI is 10-30 mg per dose, administered sublingually, as needed
KYNMOBI doses should be separated by at least 2 h
Maximum of 5 doses per day; maximum single dose is 30 mg
Mechanism of action
KYNMOBI is a nonergoline dopamine agonist with a high in vitro binding affinity for dopamine D4 receptor and moderate affinity for the dopamine D2, D3, and D5, and adrenergic a1D, a2B, a2C receptors.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the KYNMOBI description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
Elaborated details on KYNMOBI regulatory milestones and other development activities have been provided in this report.
The report also highlights the KYNMOBI research and development activities in Parkinson's disease across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around KYNMOBI.
The report contains forecasted sales of KYNMOBI for Parkinson's disease till 2032.
Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
The report also features the SWOT analysis with analyst views for KYNMOBI in Parkinson's disease.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
KYNMOBI Analytical Perspective by DelveInsight
In-depth KYNMOBI Market Assessment
This report provides a detailed market assessment of KYNMOBI for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
KYNMOBI Clinical Assessment
The report provides the clinical trials information of KYNMOBI for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KYNMOBI dominance.
Other emerging products for Parkinson's disease are expected to give tough market competition to KYNMOBI and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KYNMOBI in Parkinson's disease.
Our in-depth analysis of the forecasted sales data of KYNMOBI from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KYNMOBI in Parkinson's disease.
Key Questions:
What is the product type, route of administration and mechanism of action of KYNMOBI?
What is the clinical trial status of the study related to KYNMOBI in Parkinson's disease and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KYNMOBI development?
What are the key designations that have been granted to KYNMOBI for Parkinson's disease?
What is the forecasted market scenario of KYNMOBI for Parkinson's disease?
What are the forecasted sales of KYNMOBI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to KYNMOBI for Parkinson's disease?
Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
